Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of body tissue composition on the outcome of patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors.
Makrakis D, Rounis K, Tsigkas AP, Georgiou A, Galanakis N, Tsakonas G, Ekman S, Papadaki C, Monastirioti A, Kontogianni M, Gioulbasanis I, Mavroudis D, Agelaki S. Makrakis D, et al. PLoS One. 2023 Feb 10;18(2):e0277708. doi: 10.1371/journal.pone.0277708. eCollection 2023. PLoS One. 2023. PMID: 36763597 Free PMC article.
A Phase 1/2 Study of Rapamycin and Cisplatin/Gemcitabine for Treatment of Patients With Muscle-Invasive Bladder Cancer.
Makrakis D, Wright JL, Roudier MP, Garcia J, Vakar-Lopez F, Porter MP, Wang Y, Dash A, Lin D, Schade G, Winters B, Zhang X, Nelson P, Mostaghel E, Cheng HH, Schweizer M, Holt SK, Gore JL, Yu EY, Lam HM, Montgomery B. Makrakis D, et al. Clin Genitourin Cancer. 2023 Apr;21(2):265-272. doi: 10.1016/j.clgc.2022.12.003. Epub 2022 Dec 23. Clin Genitourin Cancer. 2023. PMID: 36710146 Clinical Trial.
Circulating MicroRNAs Regulating DNA Damage Response and Responsiveness to Cisplatin in the Prognosis of Patients with Non-Small Cell Lung Cancer Treated with First-Line Platinum Chemotherapy.
Papadaki C, Monastirioti A, Rounis K, Makrakis D, Kalbakis K, Nikolaou C, Mavroudis D, Agelaki S. Papadaki C, et al. Among authors: makrakis d. Cancers (Basel). 2020 May 19;12(5):1282. doi: 10.3390/cancers12051282. Cancers (Basel). 2020. PMID: 32438598 Free PMC article.
Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study.
Rounis K, Makrakis D, Papadaki C, Monastirioti A, Vamvakas L, Kalbakis K, Gourlia K, Xanthopoulos I, Tsamardinos I, Mavroudis D, Agelaki S. Rounis K, et al. Among authors: makrakis d. PLoS One. 2021 Jun 1;16(6):e0252537. doi: 10.1371/journal.pone.0252537. eCollection 2021. PLoS One. 2021. PMID: 34061904 Free PMC article.
Cancer cachexia syndrome and clinical outcome in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: results from a prospective, observational study.
Rounis K, Makrakis D, Tsigkas AP, Georgiou A, Galanakis N, Papadaki C, Monastirioti A, Vamvakas L, Kalbakis K, Vardakis N, Kontogianni M, Gioulbasanis I, Mavroudis D, Agelaki S. Rounis K, et al. Among authors: makrakis d. Transl Lung Cancer Res. 2021 Aug;10(8):3538-3549. doi: 10.21037/tlcr-21-460. Transl Lung Cancer Res. 2021. PMID: 34584855 Free PMC article.
Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer.
Makrakis D, Talukder R, Diamantopoulos LN, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Koshkin VS, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Santos VS, Agarwal N, Jain J, Zakharia Y, Morales-Barrera R, Devitt ME, Grant M, Lythgoe MP, Pinato DJ, Nelson A, Hoimes CJ, Shreck E, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Murgic J, Fröbe A, Rodriguez-Vida A, Drakaki A, Liu S, Kumar V, Di Lorenzo G, Joshi M, Isaacsson-Velho P, Buznego LA, Duran I, Moses M, Barata P, Sonpavde G, Yu EY, Wright JL, Grivas P, Khaki AR. Makrakis D, et al. BJU Int. 2022 Nov;130(5):592-603. doi: 10.1111/bju.15603. Epub 2021 Oct 25. BJU Int. 2022. PMID: 34597472 Free PMC article.
Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin.
Talukder R, Makrakis D, Diamantopoulos LN, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Koshkin VS, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Santos VS, Agarwal N, Jain J, Zakharia Y, Morales-Barrera R, Devitt ME, Grant M, Lythgoe MP, Pinato DJ, Nelson A, Hoimes CJ, Shreck E, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Murgic J, Fröbe A, Rodriguez-Vida A, Drakaki A, Liu S, Kumar V, Lorenzo GD, Joshi M, Velho PI, Buznego LA, Duran I, Moses M, Barata P, Sonpavde G, Yu EY, Wright JL, Grivas P, Khaki AR. Talukder R, et al. Among authors: makrakis d. Clin Genitourin Cancer. 2022 Apr;20(2):165-175. doi: 10.1016/j.clgc.2021.12.012. Epub 2021 Dec 17. Clin Genitourin Cancer. 2022. PMID: 35078711 Free PMC article.
35 results